Phenotypic Plasticity of Sarcomeric Protein Mutations**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 49, Issue 25, 2007, Pages 2427-2429

  Marian, Ali J ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSIDASE; CALCIUM; CYTOSKELETON PROTEIN; ION CHANNEL; PROTEIN; TROPONIN C;

CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; EDITORIAL; ENZYME REPLACEMENT; FABRY DISEASE; HEART FAILURE; HUMAN; LONG QT SYNDROME; MOLECULAR GENETICS; MUTATION; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL;

CARDIOMYOPATHY, HYPERTROPHIC; CARDIOMYOPATHY, RESTRICTIVE; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; PREVALENCE; PROGNOSIS; SARCOMERES; SURVIVAL ANALYSIS;

EID: 34250769985     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.04.016     Document Type: Editorial

References (20)

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
2. Packer M., Fowler M.B., Roecker E.B., et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 106 (2002) 2194-2199
3. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78 (1996) 902-907
4. Rosamond W., Flegal K., Friday G., et al. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) e69-e171
5. Sachdev B., Takenaka T., Teraguchi H., et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105 (2002) 1407-1411
6. Chimenti C., Pieroni M., Morgante E., et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 110 (2004) 1047-1053
7. Wilcox W.R., Banikazemi M., Guffon N., et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75 (2004) 65-74
8. Capell B.C., and Collins F.S. Human laminopathies: nuclei gone genetically awry. Nat Rev Genet 7 (2006) 940-952
9. Kamisago M., Sharma S.D., DePalma S.R., et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 343 (2000) 1688-1696
10. Kubo T., Gimeno J.R., Bahl A., et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J Am Coll Cardiol 49 (2007) 2419-2426
11. Mogensen J., Kubo T., Duque M., et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 111 (2003) 209-216
12. Daehmlow S., Erdmann J., Knueppel T., et al. Novel mutations in sarcomeric protein genes in dilated cardiomyopathy. Biochem Biophys Res Commun 298 (2002) 116-120
13. Finer J.T., Simmons R.M., and Spudich J.A. Single myosin molecule mechanics: piconewton forces and nanometre steps. Nature 368 (1994) 113-119
14. Morimoto S., Yanaga F., Minakami R., and Ohtsuki I. Ca2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol 275 (1998) C200-C207
15. Solaro R.J., Varghese J., Marian A.J., and Chandra M. Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q. Basic Res Cardiol 97 Suppl 1 (2002) I102-I110
16. Morimoto S., Lu Q.W., Harada K., et al. Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proc Natl Acad Sci U S A 99 (2002) 913-918
17. Lu Q.W., Morimoto S., Harada K., et al. Cardiac troponin T mutation R141W found in dilated cardiomyopathy stabilizes the troponin T-tropomyosin interaction and causes a Ca2+ desensitization. J Mol Cell Cardiol 35 (2003) 1421-1427
18. Robinson P., Mirza M., Knott A., et al. Alterations in thin filament regulation induced by a human cardiac troponin T mutant that causes dilated cardiomyopathy are distinct from those induced by troponin T mutants that cause hypertrophic cardiomyopathy. J Biol Chem 277 (2002) 40710-40716
19. Senthil V., Chen S.N., Sidhu J.S., Roberts R., and Marian A.J. Differences in protein-protein interactions as a basis for the contrasting phenotypes of hypertrophic and dilated cardiomyopathies resulting from different mutations in the same sarcomeric protein. J Am Coll Cardiol 47 Suppl A (2006) 62A-63A
20. Cazorla O., Freiburg A., Helmes M., et al. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res 86 (2000) 59-67